Covalon Technologies (COV) Q4 2025 earnings summary

Executive summary

• Achieved highest quarterly revenue of fiscal 2025 in Q4 at $8.7 million, marking the third consecutive year of growth, though Q4 was flat or slightly down year-over-year.

• Full-year revenue reached $32.8 million, up 5.3% from the prior year, driven by strong U.S. vascular access, surgical, and international channels.

• Paid first-ever special dividend of $0.15 per share, totaling $4.1 million, reflecting financial strength.

• Ended the year with $17 million in cash and no debt, maintaining seven consecutive profitable quarters.

• Appointed Katie Martinovich as permanent CFO.

Financial highlights

• Q4 revenue was $8.7 million, highest of the year but flat or down 2% year-over-year; full-year revenue grew 5.3% to $32.8 million.

• Gross margin for the year was 53.2% (56% excluding inventory write-offs), down from 60.7% the prior year.

• Adjusted EBITDA for the year was $3.7 million, down 24.3% year-over-year; Q4 adjusted EBITDA was $0.7 million.

• Operating expenses decreased by 6.4% year-over-year, reflecting cost discipline.

• Net income for the year was $2,058,089, down from $2,669,792.

Outlook and guidance

• Management expects accelerated growth in 2026 and beyond, driven by commercial advancement, innovation, and new strategic partnerships.

• Gross margins expected to remain in the low-to-high 50% range, potentially reaching low 60% for med tech peers.

• First purchase order from new US advanced wound care partner to be delivered in FY2026 Q2, expected to exceed $1 million.

• Disruption from a US advanced wound care partner's ownership transition is not expected to persist long-term.